- Details
- Description
-
Packaging Size56T/bottle
-
Strength200mg
-
CompositonCapmatinib
-
TreatmentcMET Lung Cancer(NSCLC)
-
FormTablet
-
BrandCampmadx
-
Quantity Unit200mg*56T/Bottle
-
ManufacturerBIGBEAR Pharma,LAOs PDR
Capmatinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.
Non-Small Cell Lung Cancer
Indicated for metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping
400 mg PO BID
Continue until disease progression or unacceptable toxicity
Dosage Modifications
Dose reductions for adverse reactions
- First occurrence: Restart at 300 mg PO BID
- Second occurrence: Restart at 200 mg PO BID
- Unable to tolerate 200 mg PO BID: Permanently discontinue
